Cadrenal Therapeutics Inc. (CVKD)
CVKD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CVKD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001937993 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern for at least one year from the date the accompanying financial statements are issued." | 10-Q 2026-08-13 |
| Cash and burn | $2.4M cash; operating cash flow -$2.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | 3,567,592 (2026-08-13); 2,046,854 a year earlier; 13,022,754 three years earlier. 3y figure adjusted for split (1-for-15 overall). | Cover page 2026-08-13 |
| Reverse splits, 3 years | 1; latest 1-for-15 on 2024-08-20 | Source 2024-08-20 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 5 424B5 takedowns, 4 at the market | Latest 2025-12-23 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WithumSmith+Brown, PC, East Brunswick, New Jersey, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $687K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.3M | -$2.2M | $2.4M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$2.5M | -$3.0M | $2.3M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | Not filed | -$3.0M | -$2.6M | $4.0M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$2.7M | -$2.4M | $3.9M | No debt tags | Needs four quarters | 10-Q 2025-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$3.7M | -$3.0M | $5.6M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$3.8M | -$4.6M | $7.3M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | Not filed | -$4.2M | -$1.8M | $10.0M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$2.4M | -$2.2M | $4.4M | No debt tags | Needs four quarters | 10-Q 2025-11-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-07-20 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-31 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-07 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-08-03 |
Source: SEC EDGAR submissions feed, 278 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +54.1% |
| 1 month | +51.5% |
| 3 months | -18.8% |
| Year to date | -77.7% |
| 1 year | -87.0% |
| From 52-week high | -87.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SCNX | Scienture Holdings Inc. | $2.99 | +3.10% | $4.9M |
| CNSP | CNS Pharmaceuticals Inc. | $3.48 | +20.42% | $5.1M |
| PULM | Pulmatrix Inc. | $1.33 | +2.31% | $4.9M |
| JAGX | Jaguar Health Inc. | $0.3864 | -7.74% | $5.2M |
| PCSA | Processa Pharmaceuticals Inc. | $1.72 | -7.53% | $4.8M |
| CANF | Can-Fite Biopharma Ltd | $1.56 | +9.86% | $4.7M |
| SKYE | Skye Bioscience Inc. | $1.06 | -2.29% | $4.7M |
| NCNA | NuCana plc American Depositary Share | $0.8631 | -7.46% | $4.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier